Posaconazole plasma concentration and inflammatory markers will be determined in all samples available from routine analysis.
A prospective observational study will be performed at the University Medical Center Groningen, the Netherlands using longitudinal data collection. The design of the study will be that patients starting on posaconazole treatment will be evaluated. After informed consent is obtained medical data will be collected from the medical chart. Posaconazole plasma concentration (trough levels) and inflammatory markers (e.g. C-reactive protein) will be determined in all samples available from routine analysis (often daily). This will result in a detailed data set capturing day to day variations in inflammation and drug concentrations.
Study Type
OBSERVATIONAL
Enrollment
64
collection plasma samples for measuring posaconazole drug concentration
University Medical Center Groningen
Groningen, Netherlands
C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/L
Posaconazole drug exposure during treatment in different stages of inflammation. To determine the differences in concentrations between patients a random additive effect was used. Additionally, to correct for differences in intervals between observations a first-order autoregressive correlation was used. The Wald type III test was used to assess the influence of inflammation on posaconazole concentration.
Time frame: 6 months after start of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.